Merck Serono, a division of German major Merck KgaA, has signed a
licensing agreement with Australia's Bionomics for the development
of treatments for multiple sclerosis and other autoimmune diseases.
Bionomics will receive $2m upfront and research funding and milestone
payments of up to 47m [euro] for each compound selected, and undisclosed
royalties.
COPYRIGHT 2008 Society of Chemical
Industry Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2008 Gale, Cengage Learning. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.
Browse by Journal Name: